Who left the compounded GLP-1 market, and what it means for you
The February 2025 shortage resolution, the enforcement deadlines that followed and a wave of manufacturer litigation pushed several of the largest consumer platforms out of compounded GLP-1 entirely. Most patients discovered it at renewal rather than in advance.
| Platform | What changed | What it sells now |
|---|---|---|
| Ro | Moved away from compounded during 2026 | Brand products, membership billed separately |
| WeightWatchers Clinic | Moved to brand-only | Brand products with a programme fee |
| Hims & Hers | Closed compounded to new patients, March 2026, after a settlement | Brand products with membership |
| Calibrate | Brand-only membership model | Programme fee plus brand medication |
| Noom Med | Published figures describe brand product | Behaviour programme plus brand |
What the exits did to the cheap end of the market
Why it happened
Shortage listing was what permitted compounding copies of the approved products at scale. FDA resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in December 2024, and set transition deadlines for 503A pharmacies and 503B outsourcing facilities in the months that followed. A court declined to pause them.
Manufacturer litigation did the rest. Platforms facing legal exposure moved to brand-only models well before any judgment, which is how a market restructures without a court deciding anything.
The practical consequence
Two things. First, any comparison written before spring 2026 that ranks these platforms for compounded GLP-1 is describing a product they no longer sell — check the verification date on anything you read.
Second, the cheap end of the market now belongs to smaller operators. That is not automatically worse, but it does raise the value of verifying the pharmacy behind a programme rather than relying on a recognisable brand.
How to reduce your exposure
Avoid long prepaid terms with a programme whose dispensing pharmacy you cannot identify. Prefer programmes naming several partner pharmacies over those with a single owned facility, because a programme with one supply route cannot reroute your prescription. And do not let supply run to zero — start any transfer before your last vial is used.